Sage Therapeutics Seen Shunning Biogen Bid -- Market Talk

Dow Jones

Jan 14, 2025

0819 ET - Sage Therapeutics is unlikely to accept Biogen's $7.22-a-share buyout bid, say analysts at Mizuho, who note the proposal implies a negative enterprise value for the biopharmaceutical company. In a research note, Mizuho's Uy Ear and Leo Watson say Biogen's bid came as a surprise to Sage's management, which believes the company is worth significantly more. Mizuho says Sage thinks Zurzuvae has "blockbuster plus" potential in postpartum depression and that there is significant value in its pipeline, including SAGE-319, which it is testing in various neurodevelopmental disorders. Sage up 1.3% to $7.60 premarket, above Biogen's takeout bid. Sage surged 35% on Monday. (colin.kellaher@wsj.com)

(END) Dow Jones Newswires

January 14, 2025 08:19 ET (13:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503783135"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503783135\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503783135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503783135","market":"nz","top_or_hot":-1,"title":"Sage Therapeutics Seen Shunning Biogen Bid -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0819 ET - <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> is unlikely to accept Biogen's $7.22-a-share buyout bid, say analysts at Mizuho, who note the proposal implies a negative enterprise value for the biopharmaceutical company. In a research note, Mizuho's Uy Ear and Leo Watson say Biogen's bid came as a surprise to Sage's management, which believes the company is worth significantly more. Mizuho says Sage thinks Zurzuvae has \"blockbuster plus\" potential in postpartum depression and that there is significant value in its pipeline, including SAGE-319, which it is testing in various neurodevelopmental disorders. Sage up 1.3% to $7.60 premarket, above Biogen's takeout bid. Sage surged 35% on Monday.  (colin.kellaher@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2025 08:19 ET (13:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sage Therapeutics Seen Shunning Biogen Bid -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSage Therapeutics Seen Shunning Biogen Bid -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-14 21:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0819 ET - <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> is unlikely to accept Biogen's $7.22-a-share buyout bid, say analysts at Mizuho, who note the proposal implies a negative enterprise value for the biopharmaceutical company. In a research note, Mizuho's Uy Ear and Leo Watson say Biogen's bid came as a surprise to Sage's management, which believes the company is worth significantly more. Mizuho says Sage thinks Zurzuvae has \"blockbuster plus\" potential in postpartum depression and that there is significant value in its pipeline, including SAGE-319, which it is testing in various neurodevelopmental disorders. Sage up 1.3% to $7.60 premarket, above Biogen's takeout bid. Sage surged 35% on Monday.  (colin.kellaher@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2025 08:19 ET (13:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0234570918.USD","symbol_name":"高盛全球核心股票组合Acc Close","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2503783135","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503783135","pubTimestamp":1736860740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0819 ET - Sage Therapeutics is unlikely to accept Biogen's $7.22-a-share buyout bid, say analysts at Mizuho, who note the proposal implies a negative enterprise value for the biopharmaceutical company. In a research note, Mizuho's Uy Ear and Leo Watson say Biogen's bid came as a surprise to Sage's management, which believes the company is worth significantly more. Mizuho says Sage thinks Zurzuvae has \"blockbuster plus\" potential in postpartum depression and that there is significant value in its pipeline, including SAGE-319, which it is testing in various neurodevelopmental disorders. Sage up 1.3% to $7.60 premarket, above Biogen's takeout bid. Sage surged 35% on Monday.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BIIB":"渤健公司","BK4588":"碎股","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4585":"ETF&股票定投概念","SAGE":"Sage Therapeutics","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Sage Therapeutics似乎回避Biogen的收购——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1,"BIIB":1},"content_text":"0819 ET - Sage Therapeutics is unlikely to accept Biogen's $7.22-a-share buyout bid, say analysts at Mizuho, who note the proposal implies a negative enterprise value for the biopharmaceutical company. In a research note, Mizuho's Uy Ear and Leo Watson say Biogen's bid came as a surprise to Sage's management, which believes the company is worth significantly more. Mizuho says Sage thinks Zurzuvae has \"blockbuster plus\" potential in postpartum depression and that there is significant value in its pipeline, including SAGE-319, which it is testing in various neurodevelopmental disorders. Sage up 1.3% to $7.60 premarket, above Biogen's takeout bid. Sage surged 35% on Monday.  (colin.kellaher@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2025 08:19 ET (13:19 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}